About Us

Vangard Overseas is a Hong Kong based holding company with research subsidiaries in the UK and one planned in the USA. Our research domains are gynaecologic carcinoma, gastrointestinal carcinoma and neurodegenerative disease. Our theranostic technology is based on the coordination chemistry and condensed matter physics of f-block elements; lanthanides, actinides combined with polyphenolic compounds; a unique research profile,

The Vangard Bioscience subsidiaries conduct their research in collaboration with notable universities and institutes in Britain, France and Germany. Our business model is distinct from the traditional bioscience start-ups in that we share the Intellectual property, patents and commercialisation rights with our research partners. They retain all publishing rights, This model enables us to optimise our staff requirements and related costs.

We are members of a small but growing translational research community engaged in Radiopharmaceutical Therapeutics (RPT). RPT is the most multi-disciplinary space in bioscience, It requires state of the science knowledge in radiochemistry, radiobiology, oncology, pharmacology, biophysics, radionuclide imaging and dosimetry. It is estimated that fewer than ten companies worldwide are dedicated to the RPT bioscience space.